GW & Wade’s Novartis NVS Stock Holding History

GW & Wade’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.06M	Sell	20,428 -4	-0%	-$386	0.07%	174
2023 Q3	$2.08M	Sell	20,432 -2,340	-10%	-$238K	0.08%	157
2023 Q2	$2.3M	Buy	22,772 +12,604	+124%	+$1.26M	0.08%	149
2023 Q1	$935K	Sell	10,168 -98	-1%	-$8.56K	0.04%	211
2022 Q4	$931K	Sell	10,266 -916	-8%	-$77.2K	0.04%	204
2022 Q3	$850K	Sell	11,182 -27,094	-71%	-$2.25M	0.04%	188
2022 Q2	$3.24M	Buy	38,276 +25,166	+192%	+$2.21M	0.15%	108
2022 Q1	$1.15M	Buy	13,110 +129	+1%	+$11.2K	0.05%	178
2021 Q4	$1.14M	Buy	12,981 +2,035	+19%	+$169K	0.05%	182
2021 Q3	$895K	Buy	10,946 +773	+8%	+$69.5K	0.04%	196
2021 Q2	$928K	Buy	10,173 +353	+4%	+$31.4K	0.04%	192
2021 Q1	$839K	Buy	9,820 +4,512	+85%	+$405K	0.04%	181
2020 Q4	$501K	Buy	+5,308	New	+$464K	0.03%	191
2016 Q4	–	Sell	-3,076	Closed	-$218K	–	233
2016 Q3	$218K	Sell	3,076 -11,874	-79%	-$865K	0.04%	206
2016 Q2	$1.1M	Buy	+14,950	New	+$1.03M	0.19%	100
2015 Q2	–	Sell	-3,096	Closed	-$274K	–	240
2015 Q1	$274K	Buy	+3,096	New	+$275K	0.05%	197

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GW & Wade's NVS Position: Q4 2023 in Review

GW & Wade reduced its Novartis (NVS) stake by 0.02% in Q4 2023, selling an estimated $386 and leaving 20,428 shares worth $2.06M. The position accounts for 0.07% of the portfolio, ranked #174.

GW & Wade first reported a position in NVS in Q1 2015 and has held it in 16 quarters since. The position peaked at $3.24M in Q2 2022. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.

GW & Wade held 20,428 shares of Novartis worth $2.06M as of Q4 2023.
GW & Wade sold 4 Novartis shares in Q4 2023, an estimated $386.
Novartis made up 0.07% of GW & Wade's portfolio in Q4 2023, its #174 holding.
GW & Wade first reported a position in Novartis in Q1 2015 and has held it in 16 quarters since.
GW & Wade's Novartis position peaked at $3.24M in Q2 2022.
1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.